Business
AI summaryVivesto develops, markets and sells drugs in human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a paclitaxel formulation using the company's XR-17 encapsulation technology for treating canine mastocytoma, and it also offers Apealea, an injectable paclitaxel formulation for various cancers, while developing Cantrixil for advanced cancer and Docetaxel micellar for prostate cancer. Formerly known as Oasmia Pharmaceutical, the company adopted the Vivesto name in March 2022; it was founded in 1988 and is headquartered in Solna, Sweden.
